US FDA Invites Warning Letter Follow-Up Inspection Alternative Proposals As Pandemic Persists
With inspectorate grounded by COVID-19, agency cannot clear remediated facilities or approve related applications – unless industry has a better idea.
You may also be interested in...
Demand surges, supply surges and investigator travel restrictions are forcing FDA to adopt less restrictive regulatory approaches during the pandemic.
Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.
Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.